Home
About Us
- Leadership & Advisors
- Contact Us
Products
- Transplant
  - VitaGraft Liver
  - VitaGraft Kidney
- Oncology
  - DetermaIO
  - DetermaCNI
- Publications
- Biopharma Services
Investors
Contact Us

News Releases

Date	Title	Document
Date Jun 15, 2021	Title EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings	Document PDF
Date Jun 03, 2021	Title Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally	Document PDF
Date Jun 01, 2021	Title Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer	Document PDF
Date May 17, 2021	Title Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update	Document PDF
Date May 06, 2021	Title Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.	Document PDF
Date May 04, 2021	Title Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17	Document PDF
Date Apr 28, 2021	Title Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting	Document PDF
Date Apr 19, 2021	Title Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.	Document PDF
Date Apr 14, 2021	Title Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors	Document PDF
Date Apr 10, 2021	Title Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™	Document PDF